In the latest trading session, 0.23 million Phathom Pharmaceuticals Inc (NASDAQ:PHAT) shares changed hands as the company’s beta touched 0.48. With the company’s most recent per share price at $5.24 changing hands around $0.4 or 8.26% at last look, the market valuation stands at $364.89M. PHAT’s current price is a discount, trading about -276.15% off its 52-week high of $19.71. The share price had its 52-week low at $4.07, which suggests the last value was 22.33% up since then. When we look at Phathom Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.46 million shares, with the 3-month average coming to 1.09 million.
Analysts gave the Phathom Pharmaceuticals Inc (PHAT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 2 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended PHAT as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Phathom Pharmaceuticals Inc’s EPS for the current quarter is expected to be -1.06.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
Instantly PHAT is in green as seen in intraday trades today. With action 9.39%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -35.47%, with the 5-day performance at 9.39% in the green. However, in the 30-day time frame, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) is -9.19% down. Looking at the short shares, we see there were 13.92 million shares sold at short interest cover period of 13.68 days.
The consensus price target for the stock as assigned by Wall Street analysts is 18, meaning bulls need an upside of 70.89% from its recent market value. According to analyst projections, PHAT’s forecast low is 18 with 18 as the target high. To hit the forecast high, the stock’s price needs a -243.51% plunge from its current level, while the stock would need to soar -243.51% for it to hit the projected low.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
Year-over-year growth is forecast to reach 195.33% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 27.75M. 7 analysts are of the opinion that Phathom Pharmaceuticals Inc’s revenue for the current quarter will be 36.86M. The company’s revenue for the corresponding quarters a year ago was 1.91M and 7.32M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1,351.14%. The estimates for the next quarter sales put growth at 403.29%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 12.50%. The 2025 estimates are for Phathom Pharmaceuticals Inc earnings to increase by 23.56%.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.77% of Phathom Pharmaceuticals Inc shares while 97.01% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 100.81%. There are 97.01% institutions holding the Phathom Pharmaceuticals Inc stock share, with FRAZIER LIFE SCIENCES MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 17.2637% of the shares, roughly 10.11 million PHAT shares worth $104.13 million.
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD holds the second largest percentage of outstanding shares, with 12.7473% or 7.46 million shares worth $76.89 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were Invesco Global Fund and PGIM Jennison Health Sciences Fd. With 1.98 shares estimated at $10.79 million under it, the former controlled 2.84% of total outstanding shares. On the other hand, PGIM Jennison Health Sciences Fd held about 2.56% of the shares, roughly 1.78 shares worth around $9.73 million.
